Spartan Bioscience Gets CE IVD Mark for 'Sample-to-Answer' CYP2C19 Testing Platform
December 23, 2010
Spartan Bioscience Gets CE IVD Mark for 'Sample-to-Answer' CYP2C19 Testing Platform
Spartan has already sold four systems to undisclosed customers in Europe and is "very close" to signing its first distribution agreement on the continent for the Spartan Rx CYP2C19 test, the company's CEO said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Spartan Bioscience Begins Italian Trial for CYP2C19 DNA Test
December 8, 2011 / PCR Insider - Canada's Spartan Bioscience Launches POC DNA Testing System for PGx Applications
August 12, 2010 / PCR Insider - Dx Focus: Akonni TruDiagnosis Studies; Spartan Bio CYP2C19 Test; Mitomics Prostate Cancer Assay
January 10, 2013 / PCR Insider - Canadian Trial Validates Spartan Bioscience's Point-of-Care Platform for PGx Applications
November 17, 2011 / PCR Insider - GenomeWeb Feature: Tools for Point-of-Care MDx Available, but Challenges Still Loom
February 28, 2013 / PCR Insider